SS Innovations Sends FDA New Study Data On SSi Mantra Robot, Expects Review Done In First Quarter Of 2027

The company filed final data from two studies on October 5 and disclosed the submission Tuesday in an 8-K.

Share
SS Innovations Sends FDA New Study Data On SSi Mantra Robot, Expects Review Done In First Quarter Of 2027

SS Innovations International answered the FDA's request for more information on its SSi Mantra surgical robot on October 5, according to an 8-K filed Tuesday. The company anticipates the agency will finish its review in the first quarter of 2027.

What the 8-K and press release say

The request came in the form of an additional-information letter tied to the company's 510(k) application, the filing a device maker submits to the FDA to show its product can be marketed. The press release attached to the 8-K says the response was submitted October 5 and announced Tuesday.

The response includes final data from an expanded human clinical and human factors validation study. It also carries final data from a bridging study the company completed in August at Hospital Internacional de Colombia in Bucaramanga, a member of the Mayo Clinic Care Network.

The 510(k) covers an initial indication of cholecystectomy, or gallbladder removal. The company said it engaged Daniel & Daniel Consulting, LLC to assist with the response, both studies and the submission.

Chairman and CEO Sudhir Srivastava said the response "brings us closer to our goal of introducing our advanced, cost-efficient SSi Mantra surgical robotic system to the U.S. market."

What it changes

The next step sits with the FDA. The company anticipates the agency will complete its review of the response and the 510(k) submission in the first quarter of 2027. That is the company's expectation, not an FDA commitment.

The release says the system has been clinically validated in India across more than 190 different types of surgical procedures. It describes the SSi Mantra as a modular system with 3 to 5 robotic arms.

SSII shares traded at $2.56 in Tuesday trading, up about 0.39% from the prior close of $2.55.

The marker to track is the FDA's review, which the company expects to conclude in the first quarter of 2027.

Sources

More on SS Innovations International

All SS Innovations International (SSII) coverage →